The biggest launches of 2022: a reboot

The biggest launches of 2022: a reboot

Source: 
EP Vantage
snippet: 

Before the fallout from Biogen's ongoing travails quashed the prospect of a fast-growing market for novel Alzheimer’s therapies, anti-amyloid-beta MAbs from Lilly and Roche sat among 2022’s biggest potential launches. Not any more.

Evaluate Vantage’s latest look at the projects approaching the market this year that are considered by the sellside to have the largest commercial potential still finds Lilly way out in front with tirzepatide. But the diabetes product is now flanked by a wider range of prospects, with Alnylam’s amyloidosis hope vutrisiran and Roche’s macular degeneration bispecific standing out.